Qure.ai, a TIME100 Most Influential Company and a global leader in digital health, has announced a new collaboration with Microsoft to broaden the availability of its AI-powered lung cancer detection, measurement, and management solutions in the United States. As part of the partnership, Qure.ai will integrate its end-to-end lung cancer suite into Microsoft’s Precision Imaging Network, enabling smoother deployment for hospitals and health systems nationwide and supporting digital transformation in clinical workflows.
Built using Large Language Models (LLMs) and Agentic AI, Qure.ai’s lung cancer algorithms are designed to enhance coordination among radiologists, pulmonologists, interventionalists, and thoracic surgeons—helping accelerate early detection, diagnosis, and treatment. Lung cancer remains the leading cause of cancer-related deaths in the U.S., claiming more lives than colon, breast, and prostate cancers combined.
Jim Mercadante, Chief Commercial Officer at Qure.ai, states, “The Qure.ai and Microsoft collaboration brings new levels of choice and simplicity for hospitals and health systems across the USA. It will power-up access to early detection, triage and tracking to improve patient care, boost survival rates and reduce overall healthcare costs. It will also bolster a growing global roster of strategic alliances between Qure.ai, academia, governments, pharmaceutical, life science and tech companies, united in advancing the digitization of health. Recently, via a long-term partnership with AstraZeneca and the EDISON Alliance, Qure.ai achieved a unique five million scan milestone across 20 countries, applying AI to routine chest X-rays to illustrate the role AI can play in earlier lung cancer risk identification.”
Peter Durlach, Corporate VP and Chief Strategy Officer, Microsoft Health and Life Sciences, adds, “The integration of Qure.ai’s AI solutions into the Precision Imaging Network will help health systems unlock new levels of efficiency - from faster detection and diagnosis to more coordinated multidisciplinary care. This collaboration reflects Microsoft’s commitment to empowering healthcare organizations with secure, scalable cloud AI solutions that enable earlier interventions, improved patient outcomes, and drive sustainable transformation across the continuum of care.”
Qure.ai currently has deployments in over 105 countries and more than 4,800 sites. Named a TIME100 Most Influential Company in 2025, it holds 19 FDA-cleared findings for identifying, triaging, and managing lung cancer and neurocritical conditions. Its lung cancer tools—which include qXR-LN for incidental nodule detection on X-ray, qCT-LN Quant for CT-based measurement, and qTrack for patient management—can be implemented individually or as a unified workflow. The company also offers qER, an FDA-cleared neurocritical solution designed to triage emergency findings and support timely interventions.
